AB Science

Founded in 2001, AB Science is a Paris-based public company with a mission to deliver innovative therapies in areas of high unmet medical need. Its strategy is anchored in the selective targeting of key pathological pathways, most notably with its lead asset masitinib, which has achieved multiple Phase 3 readouts and regulatory submissions in ALS and progressive MS. The company is advancing a diversified pipeline across oncology, neurology, and inflammatory diseases, supported by a robust intellectual property estate extending into the 2040s.

Platform for designing selective small molecule kinase inhibitors (masitinib) and novel synthetic microtubule destabilizers (AB8939) targeting specific disease pathways.

Masitinib competes with approved symptomatic and disease-modifying therapies in ALS and MS but is differentiated by its selective mast cell/microglia target. AB8939 enters a competitive AML landscape but aims to overcome resistance to existing chemotherapies through a novel mechanism of action.